RecruitingHepatocellular Carcinoma
Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Monitoring Circulating Tumor DNA
Eligible age
18+ yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of the REMNANT study is to confirm the clinical value of detecting a new biomarker, ctDNA (circulating tumor DNA), in the follow-up of patients with operated liver cancer. In order to meet this objective, this biomarker will be measured in your blood before and after surgery, at three and six months.
Sponsor: University Hospital, Rouen
You may qualify if…
- ✓ 1. Age ≥ 18 years
- ✓ 2. HCC diagnosed on consensus radiological criteria in cirrhotic patients (EASL-EORTC 2012): helical CT or MRI with triple arterial, portal and late acquisition. The diagnosis is based on the presence of hypervascularization at the early arterial time (wash-in) with wash-out (hypodensity or hypointensity compared to non-tumor liver parenchyma) at the portal phase or late phase compared to non-tumor parenchyma.
- ✓ 3. HCC diagnosed histologically in the absence of a diagnosis on imaging (see IC n°2 above)
- ✓ 4. Patient operated on for liver resection or radiofrequency destruction
- ✓ 5. Treatment decision validated by the digestive oncology PCR
- ✓ 6. Patient having read and understood the information letter and signed the non-opposition form
- ✓ 7. Patient follow-up at the Charles Nicolle University Hospital in Rouen
You may not qualify if…
- ✕ 1. Other active cancer or hematological malignancy
- ✕ 2. Contra-indication to surgery
- ✕ 3. Patient not affiliated to the social security system
- ✕ 4. Pregnant woman or parturient or breastfeeding
- ✕ 5. Person under court protection, sub guardianship or curatorship
Source: ClinicalTrials.gov · NCT05375370 · last updated 2026-02-06